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Abstract
Anthrax is a zoonotic disease caused by Bacillus anthracis, which has multiple routes of infection 
in humans, manifesting in different initial presentations of disease. Because B anthracis has the 
potential to be used as a biological weapon and can rapidly progress to systemic anthrax with high 
mortality in those who are exposed and untreated, clinical guidance that can be quickly 
implemented must be in place before any intentional release of the agent. This document provides 
clinical guidance for the prophylaxis and treatment of neonates, infants, children, adolescents, and 
young adults up to the age of 21 (referred to as “children”) in the event of a deliberate B anthracis 
release and offers guidance in areas where the unique characteristics of children dictate a different 
clinical recommendation from adults.
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INTRODUCTION
Bacillus anthracis is often placed at or near the top of potential threat agents by biodefense 
experts.1–3 Because of the potential use of B anthracis as a biothreat agent, clinical guidance 
that can be quickly implemented must be made available for review by clinicians before its 
use in a bioterrorism event, such as the intentional release of aerosolized spores. It is a rod-
shaped bacterium present in the environment and may also exist in a spore form that is easy 
to disperse. It can remain a potential hazard for weeks to years after bioterror dispersal. 
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Anthrax infection in humans can develop after exposure at different anatomic sites and can 
manifest in different clinical presentations, including cutaneous, inhalation, and 
gastrointestinal, all of which can disseminate and lead to meningoencephalitis. Another form 
of anthrax, injection anthrax, has recently been described in drug users and is associated 
with contaminated heroin use.4 This form of anthrax will not be addressed in this report. 
Most types of anthrax carry a high mortality, including cutaneous infection if local disease 
of the skin or mucosal surfaces is untreated and progresses to systemic disease.2,5,6 Toxins 
mediate much of the morbidity and mortality associated with B anthracis, including 
hemorrhage, edema, and necrosis.7
The potential danger of B anthracis as a bioweapon was dramatically illustrated after an 
accidental release of spores in 1979 from a military microbiology facility in Sverdlovsk, 
Union of Soviet Socialist Republics, that resulted in at least 77 cases of human anthrax and 
68 deaths.8 However, none of the cases reported in this incident involved children. B 
anthracis was also used as a bioweapon in 2001, when spores were intentionally distributed 
through the US postal system. Of the 22 resulting cases, 18 had confirmed anthrax, 11 of 
which had inhalation anthrax; 5 of these cases were fatal.9 The other 11 cases, both 
suspected and confirmed, were nonfatal cutaneous anthrax, 1 of which occurred in a 7-
month-old infant, whose disease progressed to systemic illness.10
This document provides clinical guidance for the prophylaxis and treatment of children in 
the event of an intentional B anthracis release and offers guidance in areas in which the 
unique characteristics of children dictate a different clinical recommendation from that for 
adults. A comprehensive review of anthrax as it relates to naturally occurring infection is not 
provided. Rather, the document gives guidance on caring for children after an intentional 
release of B anthracis when public health officials are recommending prompt prophylaxis of 
individuals thought to be exposed and rapid treatment of individuals with potential anthrax 
infection. Guidelines for both treatment and prevention in adults have been developed and 
are not reviewed in this document.11
Children require special considerations for prophylaxis and treatment, because the clinical 
presentation and progression of disease for cutaneous, inhalation, gastrointestinal, 
meningoencephalitis, and disseminated anthrax infection may be different from those in 
adults. For example, children could be at a higher risk of developing disseminated, systemic 
disease and/or meningoencephalitis after focal infection. It may be more difficult to 
diagnose the infection in children by clinical signs and symptoms early in the course, 
because febrile and respiratory illnesses, which may mimic early symptoms of anthrax, are 
common in children compared with adults. Furthermore, the signs and symptoms for any 
type of anthrax infection in infants younger than 2 months are not well defined.12
In addition, antimicrobial selection and clinical care may be different for children. Young 
children, as well as children, adolescents, and young adults with disabilities, may have 
difficulty swallowing oral tablets; compliance also may be reduced with poortasting 
suspensions.13 The safety and tolerability of some antimicrobial agents when prescribed for 
children continuously for weeks to months are not well-studied.
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Although the provision of antimicrobial agents and vaccine to asymptomatic children for 
postexposure prophylaxis (PEP) falls under the aegis of public health authorities, local 
health care providers should be familiar with available resources during a public health 
emergency to be prepared to treat symptomatic children (ambulatory and hospitalized) who 
present with focal or systemic infection. In addition, pediatric health care providers will 
likely receive questions about antimicrobial prophylaxis regimens from families and will be 
called on to provide reassurance and guidance to families, specifically regarding adverse 
effects of the prophylactic antimicrobial agents. Pediatricians and others who provide health 
care to children will be involved in this process as trusted sources of health care information 
for their patients and families. Clear lines of communication between clinicians and public 
health practitioners will help families receive consistent messages, improve disease 
surveillance and adherence to prophylactic antimicrobial regimens, decrease panic among 
parents and caregivers, and possibly save lives in the midst of a public health emergency.
The American Academy of Pediatrics (AAP) has developed a Pediatric Preparedness 
Resource Kit14 to encourage partnerships and joint decision-making between pediatricians 
and state and/ or local health department representatives. This kit includes information and 
strategies that will help to promote strategic communications and effective messaging in a 
situation such as a B anthracis release (see www.aap.org/disasters/resourcekit).
Information and guidance that is specific to the identified exposure after a bioterror release 
in which spores intentionally target civilians will be provided on the Centers for Disease 
Control and Prevention (CDC) Web site to assist pediatric health care providers with critical 
decision-making when dealing with patients, families, health care facilities, and local health 
departments (www.cdc.gov/anthrax).
This guidance reflects a comprehensive review of the literature and the opinions of 
individual experts from the AAP and the CDC (referred to as the AAP and CDC Pediatric 
Anthrax Writing Group) at the time of publication, based on the proceedings of a jointly 
sponsored workshop, held at the CDC Tom Harkin Global Communications Center in 
Atlanta, Georgia, in November 2012.
Guidance for pediatric anthrax clinical management is provided in Appendices 1 through 8, 
which are ordered based on severity of disease to offer easy access in the event of a public 
health emergency.
CLINICAL PRESENTATIONS OF ANTHRAX
B anthracis is an aerobic, gram-positive, encapsulated, spore-forming, nonhemolytic, 
nonmotile, rod-shaped bacterium. It causes an acute infection called anthrax that can 
manifest differently according to the route of exposure: cutaneous, inhalation, and 
gastrointestinal. Each of these forms can progress to systemic disease, which may present 
clinically with signs of septicemia with the subsequent development of meningoen-
cephalitis.15
Exposure to aerosolized B anthracis is likely to result in a predominance of inhalation and 
cutaneous anthrax cases; however, gastrointestinal cases also may occur. The clinical 
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presentations as discussed herein are primarily from reports of anthrax in previously healthy 
adults. Different clinical presentations may occur across the spectrum of pediatric age 
groups and in special pediatric populations, such as those with underlying comorbidities or 
disabilities.
Cutaneous Anthrax
Approximately 95% of naturally acquired cases of anthrax are cutaneous. Clinical disease in 
children appears to be similar to adults, spanning the spectrum from localized to systemic 
disease.16 One of the youngest documented cases of cutaneous infection occurred in a 1-
month-old infant who was hospitalized with B anthracis infection around the mouth, 
presumed to have been acquired from his mother with cutaneous anthrax.17
With cutaneous anthrax, after an incubation period of 1 to 12 days, the skin lesion 
progresses over 2 to 6 days from a pruritic papule or vesicle into a characteristic depressed 
black eschar surrounded by moderate to severe edema. The lesion is typically painless and 
can be accompanied by fever, malaise, headache, and painful lymphadenopathy.12,18 The 
mortality rate for cutaneous anthrax is less than 1% if treated with antimicrobial agents but 
can be as high as 20% if untreated.12,16,17,19 Those with symptoms or signs of systemic 
involvement or with lesions that involve the head, neck, or upper torso or that are large, 
bullous, multiple, or surrounded by significant edema have higher mortality rates.16,19
Inhalation Anthrax
Inhalation anthrax has the highest case-fatality ratio of the typical forms of the disease. After 
being inhaled into the lungs, B anthracis spores are transported by macrophages and other 
phagocytic cells to regional lymph nodes, where either en route or on arrival they can 
germinate into toxin-producing bacteria. The bacteria and toxins cause systemic anthrax. 
Spores may germinate as soon as 1 day or may remain dormant for weeks or months before 
germinating.20,21 Depending on the circumstances of exposure, the inhalation form of 
anthrax may be the most prevalent form of serious, life-threatening disease after an anthrax 
attack. The incubation period for inhalation anthrax in humans is not well-defined and has 
ranged from 1 to 43 days, which may reflect delayed germination of inhaled spores or 
repeated inhalation of spores from the environment after the original exposure event.8 Initial 
nonspecific signs and symptoms may include mild fever, fatigue, myalgia, and cough, and 
can resemble a viral respiratory illness.22 Occasionally, these prodromal signs and 
symptoms briefly improve before abrupt deterioration7,23,24 to a more fulminant disease 
characterized by diaphoresis, stridor, dyspnea, hypotension, or acute respiratory 
distress.7,20,23,25 These patients may develop sepsis accompanied by cyanosis, shock, and 
hemorrhagic pneumonia. Hemorrhagic pleural effusions often develop. Other organ systems, 
particularly the central nervous system (CNS), also can be affected secondary to bacteremia, 
a frequent occurrence in children noted with certain bacterial pathogens. The risk of 
meningoencephalitis is not well-defined in children, but in adults with systemic disease, it 
appears to occur in approximately 50% of cases.22,25,26
In the 5 pediatric inhalation anthrax cases reported from 1900 to 2005, nausea, vomiting, 
headache, dyspnea, or meningeal signs were exhibited, and 3 of the 5 children died.27 With 
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prompt diagnosis, initiation of combination antimicrobial therapy, and modern critical care, 
the mortality rate observed in adults with inhalation anthrax dropped from more than 90% 
for the whole 20th century to 45% in the exposures linked to letters contaminated with B 
anthracis spores in 2001,23 which suggests that better outcomes are also likely to occur in 
children. In 200628 and 2011,29 adults in Pennsylvania and Minnesota, respectively, were 
successfully treated for naturally acquired inhalation anthrax, demonstrating the 
effectiveness of modern treatments.
Gastrointestinal Anthrax
Gastrointestinal anthrax can occur after the consumption of food contaminated with B 
anthracis vegetative cells or spores. After an incubation period of 1 to 7 days after ingestion 
of bacilli or spores, gastrointestinal anthrax presents with signs and symptoms that can 
include severe abdominal pain and tenderness, nausea, vomiting, hematemesis, anorexia, 
and fever progressing to more severe systemic illness.20,30–32 With antimicrobial treatment, 
gastrointestinal anthrax exhibits a mortality rate of 40% or less.31
A report by Bravata et al27 indicated that the most commonly reported pediatric 
gastrointestinal anthrax symptoms, in order from most to least common, were fever, 
abdominal pain, vomiting, diarrhea, and bloody stool.
Gastrointestinal anthrax also can manifest as oropharyngeal anthrax, which starts as a 
painless mucosal lesion in the oral cavity or oropharynx. Signs of oropharyngeal anthrax 
may include dysphagia with posterior oropharyngeal necrotic ulcers, unilateral neck 
swelling, cervical adenopathy, edema, pharyngitis, and fever. Gastrointestinal anthrax can 
progress to systemic infection.20,31
Meningeal Anthrax
In contrast to bacterial meningitis attributable to organisms, such as pneumococcus, 
meningococcus, or Haemophilus influenzae type b, B anthracis causes a hemorrhagic 
meningoencephalitis that involves both deep brain parenchymal hemorrhagic lesions as well 
as infection of the cerebrospinal fluid (CSF) in the subarachnoid space. All forms of 
systemic anthrax can progress to me-ningoencephalitis, which, to date, has been nearly 
always fatal.7,27 However, there is limited experience with treatment using currently 
available intensive care. In a systematic review of pediatric anthrax by Bravata et al,27 
meningoencephalitis developed in 7 of 22 patients with gastrointestinal anthrax and 1 of 37 
patients with cutaneous anthrax; 6 children had primary meningoencephalitis with no 
apparent focus of entry. Only 1 patient survived. In an autopsy series of adult patients from 
Sverdlovsk, 50% of fatal cases had evidence of meningeal involvement.33 Signs of 
meningoencephalitis include fever, altered mental status, meningeal signs, and seizures,34 
although in the review by Bravata et al,27 pediatric cases of meningoencephalitis presented 
with fever, headache, delirium, seizures, emesis, and diarrhea. Too few cases exist to 
provide information on differences in the clinical presentation of meningitis between adults 
and children.
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PEP TO PREVENT INFECTION
Studies have demonstrated that spores with the potential to germinate in vitro could be 
found in the lungs of nonhuman primates up to 100 days after inhalation exposure.35 
However, the potential for long-term spore survival in the environment or subsequent 
disease is unknown.36 In the setting of a large-scale release of B anthracis spores, the public 
health response will focus on protecting the exposed population with PEP. The CDC 
Advisory Committee on Immunization Practices and the AAP Committee on Infectious 
Diseases recommend a combination of antimicrobial prophylaxis for immediate protection 
during the first 60 days after exposure and immunization for long-term protection after 
exposure to B anthracis spores.18,37 Antimicrobial prophylaxis and immunization in special 
pediatric populations, such as those with underlying comorbidities or disabilities, may differ 
from those provided below.
Antimicrobial PEP
Similar to adults, all children believed to be exposed to aerosolized B anthracis spores 
should receive at least 60 days of antimicrobial prophylaxis (Appendix 1). In response to an 
anthrax release, local points of dispensing will be identified and coordinated by public 
health officials, and will receive, and subsequently dispense, an initial 10-day supply of oral 
ciprofloxacin or doxycycline (or, if pathogens are documented to be susceptible to 
penicillin, oral amoxicillin, or phenoxymethyl penicillin may be used). Clindamycin and 
levofloxacin are considered effective alternative antimicrobial agents. Providing 
antimicrobial prophylaxis to the local population within 48 hours of the initial exposure is 
the public health goal, with local supplies being supplemented by antimicrobial agents from 
other regional or national sources. In the early phases of the response, data gathered by 
federal and state public health officials will better define the exposed population within the 
10 days after that particular exposure. To minimize indiscriminate prescribing and use of 
antimicrobial agents during the early phases of the response to an event, practitioners are 
advised to seek advice from local public health officials to determine those in need of PEP. 
Individuals deemed exposed to aerosolized B anthracis spores will be notified by local 
health authorities in partnership with local professional organizations and health care 
providers to receive the first dose of anthrax vaccine adsorbed (AVA [Bio Thrax, Emergent 
BioSolutions, Rockville, MD]), instructions for the second and third AVA doses, and an 
additional 50-day supply of antimicrobial agents. This 60-day antimicrobial regimen covers 
the incubation period of the disease8,38 and provides protection until the vaccine confers 
immunity.
A limited supply of oral suspension formulations of recommended PEP antimicrobial agents 
will be available, and distribution strategies will be determined by public health authorities 
at state and local levels. If oral suspensions are not readily available, doxycycline tablets 
will be provided with clear directions, as recommended by the US Food and Drug 
Administration (FDA), on how the tablets can be crushed and added to a food or liquid to 
create a formulation that is more palatable and designed to improve adherence for those who 
are unable to swallow a tablet.39
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Tetracycline-based antimicrobial agents, including doxycycline, may cause permanent tooth 
discoloration for children younger than 8 years if used for repeated treatment courses. 
However, doxycycline binds less readily to calcium compared with older tetracyclines, and 
in some studies, doxycycline was not associated with visible teeth staining in younger 
children.40,41 Although no prospective data exist on staining of teeth in children younger 
than 8 years taking a 60-day course of doxycycline, the benefits of preventing life-
threatening anthrax infection outweigh the potential risks of injury to teeth. Similarly, 
although no prospective data exist on the risks of cartilage toxicity with ciprofloxacin, 
particularly for a 60-day course, the benefits of an extended course for prophylaxis in 
children outweigh the concerns for potential cartilage toxicity. On the basis of availability, 
either antimicrobial agent may be used and should provide equivalent efficacy, although 
prospective data after B anthracis bioterror exposure in children do not exist.42 Some 
experts believe that if adverse events occurred with an equal incidence between doxycycline 
and ciprofloxacin, the potential for tooth staining as a sequela may be less serious than the 
potential for long-term cartilage injury.
Additional liquid formulations, such as amoxicillin and liquid suspension forms of 
doxycycline and ciprofloxacin, may be available in this additional 50-day antimicrobial 
agent supply for infants and young children or children, adolescents, and young adults with 
disabilities after the initial 10-day prophylaxis supply has been completed and the 
antimicrobial resistance profile of the B anthracis strain has been determined.
Vaccine PEP
AVA contains proteins from a sterile, cell-free, culture fluid grown from a B anthracis strain 
and contains no live or dead bacteria. All exposed adults are expected to receive AVA 
intramuscularly or subcutaneously at 0, 2, and 4 weeks in addition to a total of 60 days of 
antimicrobial prophylaxis.11 AVA has been shown to be safe and immunogenic in clinical 
trials in adults.37 Serious adverse events after AVA administration in adults were infrequent. 
However, local adverse events, such as pain, erythema, induration, and swelling, were 
common.37 Most of these local adverse events were not serious, and self-resolved. The 
vaccine, usually given as a 0.5-mL dose, contains 0.6 mg of aluminum (as aluminum 
hydroxide). A 0.5-mL dose of diphtheria, tetanus, acellular pertussis (DTaP [pediatric 
formulation] or TdaP [adolescent/adult formulation]) vaccine may contain up to 0.85 mg of 
aluminum. Local adverse events may be similar to those described in adults administered 
AVA and in children administered other vaccines, with similar aluminum hydroxide 
concentrations.
On the basis of routine and extensive use of similar vaccines in children 6 weeks of age and 
older, it is anticipated that AVA should demonstrate immunogenicity to B anthracis 
protective antigen necessary to provide protection against symptomatic infection in children 
6 weeks and older. The safety profile should to be similar to that in adults, commensurate 
with prevention of life-threatening infection. However, studies of AVA in children younger 
than 18 years have not been conducted, and the vaccine is not currently approved by the 
FDA for use in children. Until there are sufficient data to support FDA approval, AVA will 
be made available for children at the time of an event as an investigational vaccine through 
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an expedited process that will require institutional review board approval, including the use 
of appropriate consent documents. Information on the process required for use of AVA in 
children will be available on the CDC Web site at the time of an event (www.cdc.gov/
anthrax), as well as through the AAP and the FDA. All exposed children 6 weeks and older 
should receive 3 doses of AVA at 0, 2, and 4 weeks in addition to 60 days of antimicrobial 
chemoprophylaxis. The recommended route of vaccine administration in children is 
subcutaneous, although both subcutaneous and intramuscular injections appear to achieve 
similar levels of immunogenicity in 60 days. Children younger than 6 weeks should 
immediately begin antimicrobial prophylaxis but delay starting the vaccine series until they 
reach 6 weeks of age.
For children, a local adverse event to a previous dose of AVA is not a contraindication to 
receiving additional doses, although the subsequent dose should be administered at an 
alternate site. Large local reactions or systemic adverse events should be evaluated before 
additional doses are administered. Given the short time intervals between the 3 doses 
recommended for PEP, parental concerns about local adverse events should be addressed 
prospectively to increase the likelihood of adherence with the full vaccination schedule.
PEP use of AVA is not yet an FDA-approved indication in any population. The doses for 
each pediatric age group that balance immunogenicity, safety, and protective efficacy have 
not yet been determined. Clinical guidance for use of AVA in infants and children is 
currently based on data from adult AVA clinical trials and expert opinion, although 
recommendations for preevent limited investigation of AVA in children are under 
consideration. The Presidential Commission for the Study of Bioethical Issues recommends 
that preevent pediatric research into medical countermeasures, including AVA 
administration, should pose only a minimal risk to children and should use an age de-
escalation process to determine study participation risk.43 This process would look at safety 
in 18-year-olds and then progressively assess safety and risk at younger ages. Studies that 
may cause “no more than a minor increase over minimal risk” will require national review 
under federal regulations. Local institutional review boards should be aware of their role, 
before a bioterror event, in facilitating the appropriate use of AVA in children during an 
event. Federal agencies are collaborating on ways to streamline the consent process in a 
public health emergency. The intent of all providers and federal agencies is to ensure that all 
children exposed during an event have appropriate access to vaccine.
Special Vaccination Considerations
AVA should not be coadministered routinely with standard childhood vaccines during an 
anthrax bioterror event. The coadministration of routine vaccines to children in addition to 
the recommended 3 doses of AVA within 6 weeks of the final AVA immunization could 
contribute to increased adverse reactions, resulting in a reduction in adherence to full 
vaccine schedules for both routine vaccines and AVA. In addition, research on the effect of 
anthrax vaccine on the immunogenicity of routine vaccines has not been performed. Infants 
and children who are hospitalized yet still exposed during an anthrax bioterror event should 
be vaccinated by using the same schedule as outpatients. Given the host immune response 
normally documented with infection, those with anthrax infection may not require 
Bradley et al. Page 8













immunization, but systematically collected data on immunity after infection are not 
available; therefore, these children also should receive all 3 AVA vaccine doses.
Immunization of children exposed to aerosolized B anthracis spores with AVA is a priority, 
above routine immunizations. Although data are not available in children regarding the types 
and frequency of adverse events after immunization, or whether administering AVA as soon 
as a few days after the receipt of routine immunizations will lead to an increased frequency 
of adverse events, the benefits of AVA in children exposed to aerosolized B anthracis spores 
are currently believed to outweigh these risks.
Routine immunizations should resume 4 weeks after the last AVA dose.
INFECTION CONTROL IN THE HOSPITAL AND COMMUNITY
If patients have had recent exposure to aerosolized B anthracis spores, the risk of 
aerosolization of spores from clothing or skin and subsequent inhalation is unknown but not 
believed to be high.44 Public health officials, in collaboration with the CDC, will issue 
recommendations, which will be available on the CDC Anthrax Web site (www.cdc.gov/
anthrax), on how the public should decontaminate clothing and other surfaces after 
exposure, as well as how to decontaminate dwellings and public places where children may 
be present, such as schools and child care centers.
Human-to-human transmission of anthrax itself is exceedingly rare and described only in 
association with exposure to cutaneous lesions.45 Transmission through nonintact skin 
contact with draining lesions is possible; therefore, use Contact Precautions if a large 
amount of uncontained drainage is present. Cutaneous lesions will no longer contain 
vegetative bacilli within 24 hours of starting antimicrobial therapy.46 Hand washing with 
soap and water is preferable to use of waterless alcohol-based antiseptics, because alcohol 
does not have sporicidal activity. Patient care itself does not appear to pose a risk for 
transmission to health care providers.47 Although Standard Precautions for patient care and 
disposal of blood and potentially contaminated body fluids adequately address 
contagiousness from vegetative bacilli, the presence of spores in contaminated body fluids, 
dressings, and patient linens may require additional sanitizing or disposal measures. 
Incineration or steam sterilization (121°C for 30 minutes) will destroy spores. Advice on 
infection control measures that address the need for incineration or steam sterilization will 
be made, specific to an anthrax event, on the CDC Anthrax Web site (www.cdc.gov/
anthrax).
Anthrax PEP is not required for health care workers or other patient contacts as a result of 
exposure to the patient. However, health care workers and other patient contacts might 
require PEP depending on other exposure risks. A private room is unnecessary, and Standard 
Precautions should be used for patient care, including patient transport.
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MANAGEMENT OF PATIENTS WITH SUSPECTED AND CONFIRMED 
ANTHRAX
General Diagnostic and Treatment Considerations
Diagnosis—The initial evaluation of patients with any form of anthrax after a biological 
weapon exposure should be based on careful clinical examination and laboratory testing of 
sites of presumed infection. A Gram stain is likely to be the only rapid method for 
identifying B anthracis readily available in a clinical laboratory. The organism is 
characterized as a gram-positive bacillus that forms long chains of vegetative cells with a 
“jointed bamboo-rod” appearance in culture or short chains of 2 to 4 cells in direct clinical 
samples. The organism can be isolated from specimen cultures of blood; skin; respiratory 
secretions; vesicular, pleural, or ascetic fluid; or stool, as well as from CSF (Appendix 7). 
Given the high rates of meningoencephalitis in children who have signs and symptoms of 
systemic anthrax, lumbar puncture should be performed as resources permit, unless 
clinically contraindicated (such as suspected increased intracranial pressure).27 Gram-
positive bacilli with typical morphology found on unspun peripheral blood smears or in 
vesicular fluid or CSF are highly suggestive of anthrax.15
Although most clinical laboratories can provide preliminary culture results, they may not be 
able to perform sophisticated confirmatory tests, such as polymerase chain reaction (PCR) 
assay on patient specimens (blood, serum, lesion swabs), lethal factor detection analysis, and 
immunohistochemical staining of tissue, which are available through local or state public 
health laboratories or the CDC. Public health laboratories in the Laboratory Response 
Network (www.bt.cdc.gov/lrn/), a national network of local, state, and federal public health 
laboratories, can identify B anthracis by standard culture methodology in addition to other 
methods and can perform antibacterial drug susceptibility testing. For current information on 
the availability and types of traditional confirmatory tests, as well as newly developed 
molecular tests, that can be performed by public health authorities, particularly during a 
biological weapon exposure, visit the CDC Anthrax Web site. (www.cdc.gov/anthrax/labs/
labresearch.html).
Treatment—The production of toxins and the frequent occurrence of meningoencephalitis, 
as well as the presence of latent spores, must be taken into account when selecting 
antimicrobial agents and the duration of treatment of anthrax. Most of the data used to make 
these recommendations are based on historical information collected before availability of 
many of the antimicrobial agents discussed, in vitro studies, and limited nonhuman primate 
studies. Treatment data that are available almost uniformly come from adult patients. For 
many of the antimicrobial agents discussed herein, limited pharmacokinetic data are 
available to make dosing recommendations for anthrax, particularly for young infants and 
neonates. However, systemic anthrax can be a rapidly lethal disease in humans, so in the 
absence of compelling, well-documented adverse safety data in children, the most effective 
antimicrobial agents used in the adult population also should be made available for use in 
children. Children may require larger doses per kilogram of body weight and more frequent 
dosing for certain antimicrobial agents to achieve a therapeutic exposure equivalent to that 
documented to be effective for adults. The recommended doses must be sufficient to ensure 
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a therapeutic antimicrobial exposure required for life-threatening infection (ie, doses that 
achieve adequate exposure in more than 98% of all children treated). Antimicrobial dosing 
regimens, both empirical and definitive, for all anthrax clinical presentations in children and 
neonates are provided in Appendix 2 (cutaneous anthrax without systemic illness), 
Appendix 3 (systemic anthrax to include inhalation and gastrointestinal infection, without 
meningitis), Appendix 4 (systemic anthrax to include inhalation and gastrointestinal 
infection, with meningitis), and Appendix 6 (dosing in preterm and term neonates 32 to 44 
weeks’ postmenstrual age).
After an exposure to B anthracis aerosolized spores, patients treated for any form of anthrax 
are at risk for lateoccurring inhalation anthrax from residual ungerminated spores that may 
remain in the lungs for several weeks or months after an inhalation event. Depending on the 
patient’s immune status and age, as well as the type of antimicrobial agent used, some 
patients recovering from severe systemic disease will develop an immune response that 
would provide protection against germination of any remaining spores. However, if 
antimicrobial therapy is initiated early in the illness, the immune response may be blunted,38 
thus requiring continuation of antimicrobial therapy over several weeks to clear organisms 
as they emerge from the spore form. There is evidence that symptomatic nonhuman primates 
that are bacteremic with B anthracis and treated with antimicrobial agents for at least 10 
days develop an immune response and do not develop clinical disease attributable to 
retained spores that germinate after discontinuation of antimicrobial therapy.48 However, no 
data exist in either adults or children to identify which infected people may develop 
protective immunity and at what time after clinical infection. No commercially available 
assay currently exists that can determine adequate immunity to anthrax.
Children with active infection, either cutaneous or systemic, whose original exposure source 
was aerosolized spores, should complete initial antimicrobial treatment, then transition to 
oral PEP to prevent relapse from surviving B anthracis spores within the lung that may 
subsequently germinate. The duration of antimicrobial therapy to prevent relapse is not well 
established. On the basis of incubation times of up to 43 days in humans and 58 days in 
animals exposed to aerosol challenge, a full 60-day course of an oral antimicrobial agent is 
recommended to complete treatment and prophylaxis.8,38,49 Therefore, once the treatment 
course for the active infection is completed, patients should continue with antimicrobial 
prophylaxis so that they receive antimicrobial treatment for a total of 60 days.
Naturally occurring B anthracis is very likely to be susceptible to penicillin; although 
genetic material that codes for the presence of a penicillinase is present, regulation of these 
genes may be deficient.50,51 Most strains are resistant to cephalosporins.52 Further, the 
naturally occurring strains that are penicillin-resistant remain susceptible to amoxicillin/
clavulanate. Given the relative safety and tolerability of the penicillin-class agents in 
children, most pediatric experts prefer these antimicrobial agents for treatment and 
antimicrobial prophylaxis if pathogens are documented to be susceptible. Other 
antimicrobial classes, such as fluoroquinolones or tetracyclines, are likely to exhibit poorer 
tolerance and increased toxicity, especially during prolonged treatment.
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A theoretical concern exists that the use of penicillins as single antimicrobial agents could 
induce β-lactam resistance, especially if the number of organisms present is high, as can 
occur with systemic disease. In addition, infection with multidrug-resistant B anthracis, 
including bioengineered strains, is a concern.53 Therefore, public health authorities will 
monitor for the development of penicillin resistance on an ongoing basis even if strains are 
initially susceptible.
Given the potential severity of the disease, the fluoroquinolone class of antimicrobial agents 
and doxycycline (a tetracycline) are acceptable alternatives if amoxicillin and penicillin are 
not options, either because B anthracis susceptibility is unknown to either of these drugs or 
because there are other contraindications for their use in treatment. Levofloxacin and 
ciprofloxacin have been prospectively studied in children, with adequate pharmacokinetic 
data for levofloxacin use in children older than 6 months and for ciprofloxacin use in 
children older than 1 year, but less robust data are available for younger infants or neonates. 
Studies have shown a small but statistically significant increase in arthralgia in children but 
no documented increase in long-term bone or joint toxicity.54 Tetracycline-class 
antimicrobial agents, in general, are not recommended for first-line therapy of acute 
bacterial infection in children younger than 8 years (with the notable exceptions of 
rickettsial, Ehrlichia, and Anaplasma infections) because of deposition of these compounds 
in teeth and bones. Although prospective, controlled data are not available, limited 
retrospective data suggest that children who receive up to 5 standard treatment courses of 
doxycycline are not likely to have clinically detectable tooth staining.40,55
Early diagnosis and initiation of combination antimicrobial therapy is considered essential 
for treatment of systemic B anthracis infection. Although it is always better to definitively 
identify the pathogen before treatment is administered, the rapid progression of anthrax may 
not support this approach. Samples for laboratory testing should be collected before 
treatment. The AAP and CDC Pediatric Anthrax Guidance Writing Group believe that 
severe systemic infection survival can improve with combination therapy on the basis of 
theoretical considerations of different mechanisms of antimicrobial activity, drug 
penetration characteristics, synergy with combinations, increased likelihood of effective 
drug activity in case of single or multidrug resistance, and decreased likelihood of 
emergence of resistance. Combinations recommended include both a bactericidal 
antimicrobial agent and a bacterial protein synthesis inhibitor (see the section “Treatment: 
Considerations for Combination Antimicrobial Therapy for Anthrax” later in this article). 
Compared with bacteriostatic agents, bactericidal antimicrobial agents are important for 
killing vegetative forms emerging from spores and are especially effective, in general, in 
clinical outcomes when used to treat bacterial meningitis.
The high morbidity and mortality observed with anthrax is attributable primarily to 2 
exotoxins (lethal toxin and edema toxin) produced by B anthracis. Protein synthesis 
inhibitors, such as clindamycin, may decrease toxin production, as suggested with group A 
streptococcal toxic shock syndrome,56–58 which may provide an added benefit; however, 
this potential benefit has not been demonstrated in animal infection models or human cases 
of anthrax. Additional benefits may be provided by immunologic agents (such as 
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immunoglobulin or antitoxin) that bind to the protective antigen of B anthracis to prevent 
attachment to host cells, neutralize toxin activity, or promote clearance of toxin complexes.
For children with overwhelming, severe disease who are not likely to survive, pediatric 
palliative care teams, if available, may be of value to consult with treating physicians or to 
provide support to the family and child.
Cutaneous Anthrax
Diagnosis—If cutaneous anthrax is suspected, swabs of vesicular fluid, eschar tissue, or 
punch biopsy can be used to establish the diagnosis. Specimens should be submitted for 
Gram stain and culture. PCR assay and immunohistochemical staining of biopsies may be 
available through state or local public health laboratories or the CDC. The CDC provides a 
complete list of recommended specimens, including those listed previously and additionally 
blood for culture (or lethal toxin testing or antiprotective antigen serology) and swabs from 
beneath the eschar (www.cdc.gov/anthrax/labs/recommended_specimen.html).
Treatment—Localized or uncomplicated cutaneous anthrax is a less-severe disease. 
Historically, naturally acquired infection has been successfully treated in 7 to 10 days with a 
single oral antimicrobial agent, such as either amoxicillin for susceptible strains or 
ciprofloxacin, before susceptibility testing or for penicillinresistant strains (Appendix 2). 
Many patients with uncomplicated cutaneous anthrax can be treated as outpatients. 
However, hospitalization is necessary for patients with symptoms or signs of systemic 
involvement, particularly those with lesions of the head or neck that may rapidly progress to 
include edema that can compromise the airway.
The use of surgical procedures, such as incision, in the treatment of cutaneous anthrax is 
usually not required, because the lesions do not contain pus. Use of surgical procedures may 
be associated with poor outcomes.59,60 Treatment should focus instead on early initiation of 
antimicrobial agents and on local wound care. Exceptions to the general surgical 
contraindication include interventions to relieve airway obstruction or compartment 
syndrome, particularly for large or circumferential lesions of the extremities.61,62
As a child is started on therapy, cutaneous anthrax can evolve into disease with systemic 
involvement, requiring the use of intravenous combination therapy (Appendices 3 and 4). 
Children who present with cutaneous anthrax during a biological weapon–related event also 
may have inhaled spores; after treatment, they should receive additional antimicrobial 
therapy to complete a total of 60 days of therapy.
Inhalation Anthrax
Diagnosis—For suspected inhalation anthrax, a chest radiograph should be performed to 
assess for a widened mediastinum, pleural effusions, and/or pulmonary infiltrates. In a 
review of 82 cases of inhalation anthrax, abnormal radiologic findings were reported in all 
26 patients for whom chest radiographs were obtained; findings included pleural effusion in 
69% of these patients and widened mediastinum in 54%.25 Radiologic findings in children 
have been reported in only 2 children with inhalation anthrax, but typical findings, such as 
pleural effusions and widened mediastinum, were reported in both.27 If there is strong 
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suspicion of anthrax on the basis of exposure history and a questionable chest radiograph, a 
computed tomography (CT) scan of the chest may provide additional information to support 
the presumptive diagnosis.63 However, during a biological weapon event, access to 
diagnostic radiology services may become difficult; therefore, assessing risk of anthrax 
exposure or clinical signs may be used initially to determine suspicion of inhalation anthrax 
and guide management accordingly.
Extrapolating from adult data, inhalation anthrax can have a biphasic presentation with 
initial improvement, followed by precipitous hemodynamic deterioration.7,24 Because of 
this potential for sudden decompensation, patients who are hospitalized and treated for 
suspected anthrax should have careful hemodynamic monitoring, including continuous pulse 
oximetry and continuous cardiorespiratory monitoring for at least 24 to 48 hours, even if 
initial findings are reassuring.
Treatment: General Supportive Care and Ventilator Management—A review of 
inhalation anthrax cases from 1990 through 2005 showed a significant association between 
pleural fluid drainage and survival.25 High concentrations of lethal toxin have been detected 
in pleural fluid and ascites; therefore, prompt and continuous drainage by chest and/or 
peritoneal tube is critical. Ultrasonography of the chest may be a useful way to detect and 
monitor pleural fluid. Thoracotomy may be required for loculated or gelatinous effusions.
Patients with anthrax may require mechanical ventilation because of respiratory distress or 
imminent shock. In addition, some patients with anthrax may require respiratory support for 
severe edema that may occur with cutaneous lesions involving the head, neck, oropharynx, 
or thorax. Intubation or tracheostomy may be required to maintain the airway. Although 
there are significant differences between the pathophysiology of anthrax and respiratory 
distress syndrome, standard principles of ventilator management apply in both situations. 
Standard pediatric sepsis guidelines for fluids, vasopressors, blood products, and 
hemodynamic monitoring should also be followed (Appendix 7).
Treatment: Considerations for Combination Antimicrobial Therapy for 
Anthrax—The antimicrobial treatment of inhalation anthrax should follow the guidance for 
severe, systemic anthrax, both for those children for whom a lumbar puncture can be 
performed and meningitis is unlikely (Appendix 3) and those in whom meningitis cannot be 
ruled out (Appendix 4). Patients presenting with signs or symptoms suggestive of 
pneumonia or systemic anthrax should be started on combination antimicrobial therapy as 
soon as possible while awaiting results of confirmatory tests. Before recognition of a B 
anthracis biological weapon event, the differential diagnosis for a severe systemic bacterial 
infection in a child usually warranted broad-spectrum antimicrobial coverage; however, 
cephalosporin therapy, often used empirically for community-acquired infections, is not 
active against B anthracis. Once the diagnosis of anthrax is confirmed, or in the midst of a 
biological weapon exposure, individuals presenting with illness consistent with anthrax 
would warrant therapy targeted more specifically to B anthracis. Given the unique drug 
disposition in preterm and term neonates during the first month of life, specific doses for this 
age group have been provided in Appendix 6.
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Antimicrobial agents must penetrate into appropriate tissue sites, particularly into the CNS 
for children with systemic disease, especially if meningitis cannot be excluded. Meningitis 
and hemorrhagic parenchymal brain infection resulting from hematogenous spread must be 
considered in all children presenting with severe systemic anthrax.
For therapy of severe systemic anthrax in which anthrax meningitis is a consideration, 
treatment regimens for meningitis that include 2 bactericidal antimicrobial agents and 1 
proteinsynthesis inhibitor should be followed (Appendix 4). Before susceptibility testing, 
and for penicillin-resistant strains, ciprofloxacin remains the preferred bactericidal 
antimicrobial agent, in addition to meropenem. If those antimicrobial agents are not 
available, levofloxacin or imipenem should be used. For susceptible strains, penicillin G 
(intravenous) or ampicillin are recommended, in addition to ciprofloxacin, as first-line 
antimicrobial agents, avoiding the unnecessary broad-spectrum activity of meropenem. 
Linezolid is the preferred protein-synthesis inhibitor for CNS infections on the basis of 
tissue penetration characteristics (Appendix 4).
However, if meningitis has been ruled out by CSF examination and/or imaging, treatment 
may be reduced to a combination of 2, rather than 3, antimicrobial agents with activity 
against B anthracis: 1 with bactericidal activity and 1 protein synthesis inhibitor (Appendix 
3). If it is not possible to examine the CSF or perform imaging studies, but the clinical 
examination 2 to 3 days into therapy suggests that meningitis was not present by a normal 
neurologic examination, initial triple antimicrobial therapy can be stepped down to dual 
antimicrobial therapy (Appendix 3).
When meningitis is not a concern, clindamycin should be used as a protein synthesis 
inhibitor, rather than linezolid, primarily on the basis of concerns for safety. Doxycycline is 
an alternative protein synthesis inhibitor choice for treatment in all pediatric age groups for 
non-CNS anthrax. Rifampin is an additional option with the potential to provide synergistic 
antibacterial activity when used in combination with other agents if the preferred 
antimicrobial agents are not available or not tolerated.
After completing initial combination therapy for severe disease, all children with systemic 
illness, excluding meningitis, may switch to oral follow-up therapy (assuming that children 
can tolerate oral therapy and families are adherent to providing therapy) to complete a 14-
day or longer treatment course (as dictated by clinical improvement), followed by 
prophylaxis, totaling 60 days (Appendix 5). Although data on the efficacy of oral follow-up 
therapy after short-course parenteral therapy of systemic anthrax are lacking, the 
recommended antimicrobial agents all have good oral absorption characteristics and have 
been used as oral therapy of other infections in children. Children who appear to be well, 
with no ongoing signs or symptoms of active infection, may be transitioned from parenteral 
therapy to monotherapy for the remainder of their 14 days of treatment. Those for whom 
there is some degree of concern about persistent deep infection or who are slower to recover 
may be transitioned to oral therapy that includes both a bactericidal antimicrobial agent and 
a protein synthesis inhibitor for the remainder of their 14 days of treatment (Appendix 5). 
Ciprofloxacin is the preferred antimicrobial agent for penicillin-resistant strains. 
Doxycycline, clindamycin, and levofloxacin should all provide adequate singledrug therapy. 
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For penicillin-susceptible strains, amoxicillin is preferred therapy, although treating 
physicians should be aware of theoretical concerns for emergence of penicillin-resistance 
during monotherapy and be alert to the possibility of clinical deterioration as a result of 
resistance. In these situations, cultures should be obtained, if possible, to determine whether 
the organism has become resistant to amoxicillin, and the class of prescribed antimicrobial 
agent should be changed to those active against penicillin-resistant strains, as noted 
previously.
Gastrointestinal Anthrax
Diagnosis—When gastrointestinal anthrax is suspected, blood cultures should be 
performed before starting antimicrobial therapy, and culture and PCR of ascites fluid, stool 
or rectal swabs, or oropharyngeal lesions, if present, are recommended. Please see 
www.cdc.gov/anthrax/labs/recommended_specimen.html for all recommended diagnostic 
specimens for gastrointestinal anthrax.
Treatment—Antimicrobial therapy should follow the same guidance as that for systemic 
inhalation anthrax: 3 antimicrobial agents for children with possible or documented 
associated meningitis (Appendix 4) and 2 for those in whom meningitis can be excluded 
(Appendix 3).
Anthrax Meningoencephalitis
Diagnosis—Evaluation of CSF in the stable patient can provide laboratory evidence of 
meningoencephalitis as well as microbiologic confirmation of the etiology. For children too 
unstable to undergo lumbar puncture, CNS imaging by CT with contrast or magnetic 
resonance imaging with contrast should be able to document both meningeal enhancement 
characteristics of infection in addition to identification of hemorrhagic parenchymal lesions 
characteristic of anthrax meningoencephalitis. If imaging is not possible in the child with 
altered mental status or seizure activity, then clinical examination findings suggestive of 
meningitis (such as nuchal rigidity) should be presumed to be caused by 
meningoencephalitis and treated accordingly. If meningitis cannot be ruled out by 
laboratory, imaging, or physical examination, the child should be treated as though 
meningoencephalitis is present.
Treatment—Patients with confirmed or presumptive anthrax meningoencephalitis should 
be treated with 3 intravenous antimicrobial agents as noted previously in “Treatment: 
Considerations for Combination Antimicrobial Therapy for Anthrax.” All antimicrobial 
agents used should have good CNS penetration, at least 2 should have bactericidal activity, 
and at least 1 should inhibit protein synthesis (Appendix 4). It is assumed that during a 
biological weapon event, limited availability of some antimicrobial agents will exist; 
therefore, many alternative antimicrobial agents also have been listed, some lacking 
documented evidence of efficacy in CNS infections.
Intravenous ciprofloxacin is recommended as the primary bactericidal antimicrobial agent 
for meningoencephalitis on the basis of efficacy in nonhuman primate infection models and 
use in anthrax cases since 2001, unless ciprofloxacin use is contra-indicated. Levofloxacin 
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and moxifloxacin are considered equivalent alternatives to ciprofloxacin, although less 
experience is available with these antimicrobial agents in children. These fluoroquinolone 
antimicrobial agents have been shown to have adequate CNS penetration.64,65 No reports 
exist to document naturally occurring fluoroquinolone-resistant strains. However, in vitro 
resistance can be induced, which has implications for bioengineered strains.
An antimicrobial agent from the β-lactam class with activity against B anthracis is 
recommended in combination with fluoroquinolones to treat systemic anthrax cases in which 
meningitis may be present. If antimicrobial susceptibilities are unknown or if the B 
anthracis strain is resistant to penicillin, meropenem is the preferred antimicrobial agent, 
because carbapenems are stable to the β-lactamases of B anthracis, and meropenem is 
approved by the FDA for use in pediatric meningitis; however, meningoencephalitis caused 
by B anthracis has not been prospectively studied. If meropenem is not available, imipenem/
cilastatin is considered equivalent in antibacterial activity. However, imipenem/cilastatin is 
associated with an increased risk of seizures when used in the treatment of meningitis, 
presumably by lowering the seizure threshold,66,67 and should be used with caution in 
patients with suspected meningitis. Pharmacokinetic data are available for use in children. 
Limited data are available for doripenem pharmacokinetics or clinical efficacy in children, 
but if meropenem and imipenem are not available, data from experimental animal models of 
meningitis suggest similar efficacy.68 If the isolated B anthracis strain is susceptible to 
penicillin, penicillin G or ampicillin are preferred antimicrobial agents given their long 
history of use, safety profile, and narrower antimicrobial spectrum. However, as noted 
earlier, most strains contain a β-lactamase that is usually not associated with clinically 
relevant resistance but represents a potential for development of resistance to penicillin or 
ampicillin while on therapy. Emergence of resistance to penicillin would require treatment 
with meropenem or another carbapenem (Appendix 4).
Vancomycin has demonstrated in vitro activity against naturally occurring strains but has 
limited human clinical treatment data in anthrax. Vancomycin is bactericidal, achieves 
adequate CNS concentrations, has been used extensively in pediatric meningitis, and may be 
used as an alternative antimicrobial agent if β-lactam antimicrobial agents are not available 
(Appendix 4).69
At least 1 antimicrobial agent that inhibits protein synthesis is recommended for inclusion in 
the antimicrobial regimen to reduce production of exotoxins. Linezolid is recommended as 
the first-line protein synthesis inhibitor. It is recommended over clindamycin when 
meningitis is suspected or cannot be excluded, as it is likely to provide better CNS 
penetrance, although prospective, controlled data on the treatment of CNS infections with 
either antimicrobial agent do not exist.70–73 Linezolid toxicity must be taken into 
consideration. Peripheral and optic neuropathy have been reported in both adults and 
children receiving prolonged courses of linezolid.74–76 Myelosuppression is a potential 
adverse effect more commonly seen when linezolid is used for more than 14 days, but it is 
reversible and can be managed with marrow-stimulating agents.77 Linezolid should be used 
with caution in patients with preexisting myelosuppression. If patients have 
contraindications to linezolid use or it is not available, clindamycin is an acceptable 
alternative. Rifampin, although not a protein synthesis inhibitor, has been widely used for 
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antibacterial synergy with a primary drug and could be used in this capacity if neither 
linezolid nor clindamycin are available.
Chloramphenicol historically has been used to successfully treat anthrax78; it is a protein 
synthesis inhibitor with excellent CNS penetration. The intravenous form is not widely 
available in the United States, and the oral formulation is no longer available. Intravenous 
chloramphenicol would be an acceptable alternative if linezolid, clindamycin, and rifampin 
are not available for use. Doxycycline should not be used as first-line therapy if meningitis 
is suspected because of variable CNS penetration compared with fluoroquinolones and β-
lactams, but it may be effective if other preferred antimicrobial agents are not available or 
are not tolerated.
Duration of initial intravenous combination therapy is determined by meningitis risk and 
clinical response to treatment. With mortality rates for meningoencephalitis approaching 
100%, no prospective data exist on which to base recommendations for an effective 
treatment duration.69 For children with meningoencephalitis or in children for whom 
meningitis cannot be ruled out, combination therapy is recommended for a minimum of 2 
weeks, depending on the severity of disease and presence of brain parenchymal hemorrhagic 
lesions. Intravenous therapy should continue until the patient is clinically stable, with all 
clinical signs and symptoms and laboratory and imaging data documenting resolution of 
inflammation, even if required for 3 to 6 weeks. As with other forms of anthrax secondary to 
a biological weapon exposure, ongoing oral PEP therapy should continue until antimicrobial 
therapy has been administered for a total of 60 days.
Use of Corticosteroids
There are limited data to guide use of corticosteroids in anthrax. Clinicians should maintain 
a high index of suspicion for adrenal failure and perform adrenal hormone replacement 
therapy with dosing appropriate for stressed patients if adrenal failure is suspected on the 
basis of history or pressor-refractory hypotension. Although there are no randomized trials 
of corticosteroid use in human anthrax, adjunctive corticosteroids in anthrax may be 
considered for management of severe edema or meningoencephalitis. In a systematic review 
of anthrax meningitis by Sejvar et al,69 survival was slightly increased among patients with 
meningoencephalitis who received steroids compared with those who did not. Several small 
observational studies of anthrax involving the head and neck appeared to favor their use in 
this setting. Although corticosteroid doses have not been studied prospectively in anthrax, 
doses previously used in pediatric bacterial meningitis (dexamethasone 0.6 mg/kg per day, 
in divided doses every 6 hours for 4 days) should be appropriate.79
Antitoxins
Human data from the pre–antimicrobial era suggest that nonhuman anthrax antiserum 
reduced the mortality rate for cutaneous anthrax and that antiserum might be beneficial in 
inhalation anthrax. Two antitoxin products are in the Strategic National Stockpile: 
raxibacumab (a humanized monoclonal antibody) and Anthrax Immune Globulin (AIG [a 
polyclonal human immunoglobulin]). Raxibacumab is approved by the FDA for use in 
adults and children for the treatment or prevention of anthrax. On the basis of animal 
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studies, pediatric population pharmacokinetic modeling was performed by the manufacturer, 
and proposed weight-based doses for children are provided on the package label 
(www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf). AIG is not 
currently approved by the FDA and will need to be administered under an Investigational 
New Drug application or Emergency Use Authorization during a mass exposure event.
Suggested doses of antitoxin preparations for children that reflect current knowledge of the 
product will accompany raxibacumab and AIG when these products are shipped to points of 
dispensing located in proximity to the anthrax exposure site. Both products inhibit B 
anthracis protective antigen binding to the anthrax toxin receptors on human cells and 
subsequent translocation of the 2 primary toxins into cells.80
In animal studies, both raxibacumab and AIG have been shown to be effective for treatment 
of inhalation anthrax when administered without antimicrobial agents.1 Both have been 
studied in animals as adjunctive therapy with antimicrobial agents when treatment is delayed 
and appear to provide additional survival benefit. Both products have been studied in adult 
volunteers for pharmacokinetics and safety. AIG has been administered to 3 adults with 
inhalation anthrax, 1 with gastrointestinal anthrax, and 15 with injection anthrax. 
Raxibacumab has been used in animal models of inhalation anthrax but has not yet been 
used to treat human disease. The products appear to be safe and well-tolerated. Headache, 
sore throat, and nausea were the most commonly reported adverse effects with AIG, and 
rash occurred in a small number of recipients of raxibacumab. Pretreatment with 
diphenhydramine is recommended for patients who will be receiving raxibacumab 
(www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf).
The AAP and CDC recommend the use of antitoxin in addition to systemic antimicrobial 
agents for all patients with highly suspect (eg, child exposed during a bioterror event, with 
systemic signs and symptoms compatible with inhalation, gastrointestinal, or meningeal 
anthrax) or confirmed systemic anthrax. Antimicrobial agents alone can be effective if 
initiated early in the course of disease. However, given the high mortality rate of systemic 
anthrax and the apparently low risk of antitoxins, the potential benefits appear to greatly 
outweigh the risks. Data on the optimal timing are lacking, but most experts favor early 
administration. During a biological weapon event in which the number of patients with 
anthrax exceeds available antitoxin and ill patients may overwhelm the health care system, 
antitoxin should be reserved for patients most likely to benefit from it, including (1) 
noncritically ill, nonmoribund children with confirmed systemic anthrax in relatively stable 
clinical condition, and (2) critically ill nonmoribund children who may have progressive 
disease with dysfunction in 1 or more organ systems. In such an event, antitoxin should be 
added to combination antimicrobial therapy. Insufficient data are available to recommend 
one antitoxin product routinely over the other. During an event, recommendations on dosing 
will be provided with the antitoxin products.
CONSIDERATIONS FOR BREASTFEEDING INFANTS
Unless breastfeeding mothers have untreated cutaneous lesions on their breasts, mothers 
should initiate and continue breastfeeding, if able, after exposure to B anthracis spores when 
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they are undergoing treatment of disease and when they are receiving vaccine and 
antimicrobial agents for PEP. Cutaneous lesions are not considered contagious after 24 to 48 
hours of effective antimicrobial therapy. Given the various considerations of the potential 
lethality of anthrax in both the infant and mother, antimicrobial efficacy, infant safety, and 
the well-known benefits of breastfeeding, the selection of antimicrobial agents and PEP for 
breastfeeding mothers should not be modified from those for the general adult population. 
More specific recommendations for compatibility of certain antimicrobial agents and 
breastfeeding can be found in Appendix 8.
The decision with respect to PEP therapy for breastfeeding mothers should be independent 
of that for the infant,81 including the long-term use of fluoroquinolones or doxycycline. The 
safety of 60 days of infant exposure to maternal antimicrobial agents through human milk is 
largely unknown but should not in any way affect the need to appropriately treat the 
mother.82 Breastfeeding infants should receive prophylaxis as recommended, regardless of 
the prophylaxis status of the mother. Additional guidance for pregnant and lactating mothers 
may be found in a recent review from the CDC by Meaney-Delman and colleagues.83
CONCLUSIONS
The use of B anthracis as a biological weapon is considered by the US government to be a 
potential national security threat. Therefore, the clinical and public health communities must 
be prepared to dispense prophylactic antimicrobial agents, antitoxin agents, and vaccines115 
to prevent disease and treat children who develop infection. To optimally manage children 
during an anthrax bioterror event, ready access to information from public health officials by 
health care providers and information communicated back to public health officials from 
health care providers is critical. Clear recommendations and consistent messaging to the 
public from both public health officials and health care providers will be extremely 
important.
Recommendations and key considerations (main points) in a mass B anthracis exposure 
scenario include the following:
Management of Exposed but Asymptomatic Children
1 Within 48 hours of exposure to B anthracis spores, public health authorities plan 
to provide a 10-day course of antimicrobial prophylaxis to the local population 
likely to have been exposed, contingent on available resources.
2 Within 10 days of exposure, public health authorities plan to further define those 
who have had a clear and significant exposure and will require an additional 50 
days of antimicrobial PEP as well as the 3-dose AVA series under an 
Investigational New Drug application. For children younger than 6 weeks (who 
are not candidates for AVA), antimicrobial prophylaxis should begin 
immediately, but the vaccine series should be delayed until the child reaches 6 
weeks of age.
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3 A local adverse event to a prior dose of AVA is not a contraindication to 
receiving additional doses, although the subsequent dose should be administered 
at an alternate site and closely monitored.
4 Although not strictly contraindicated, AVA should not be coadministered with 
routine childhood vaccinations during an anthrax event.
Management of Disease
5 Anthrax may occur in different clinical forms, any of which may progress to 
systemic disease. Treatment will vary by clinical manifestation.
6 Cutaneous anthrax without systemic involvement that occurs in the context of an 
anthrax bioterror event should be treated with a single oral antimicrobial agent.
7 Inhalation, gastrointestinal, or other systemic disease without 
meningoencephalitis should be treated with at least 2 intravenous antimicrobial 
agents: a bactericidal agent and a protein synthesis inhibitor.
8 Systemic disease with possible or confirmed meningoencephalitis should be 
treated with 3 intravenous antimicrobial agents with adequate CNS penetration, 
including 2 bactericidal agents and a protein synthesis inhibitor.
9 Antitoxin (either AIG or raxibacumab) is recommended for children with 
anthrax systemic disease.
10 Corticosteroid adjunctive therapy may be considered in the management of 
children with severe cerebral edema or meningoencephalitis.
11 Once therapy has been completed for any form of systemic or cutaneous anthrax 
infection in children involved in an aerosol B anthracis dispersal event, 
appropriate oral antimicrobial agents should be provided to complete a full 60 
days of therapy.
12 Breastfeeding should continue for infants of mothers who require antimicrobial 
treatment or prophylaxis or anthrax vaccine.
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ABBREVIATIONS
AAP American Academy of Pediatrics
AIG anthrax immune globulin
AVA anthrax vaccine adsorbed
CDC Centers for Disease Control and Prevention
CNS central nervous system
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FDA US Food and Drug Administration
PCR polymerase chain reaction
PEP postexposure prophylaxis
APPENDIX 1 Postexposure Prophylaxis for B anthracis (for Children 1 
Month of Age and Older)
1. For penicillin-resistant strains or prior to susceptibility testing
Ciprofloxacin30 mg/kg/day, by mouth (PO), divided every 12 h (not to exceed 500 mg/dose)
OR
Doxycyclinea <45 kg: 4.4 mg/kg/day, PO, divided every 12 h (not to exceed 100 mg/dose) >45 kg: 100 mg/dose, PO, 
given every 12 h
OR
Clindamycin,b 30 mg/kg/day, PO, divided every 8 h (not to exceed 900 mg/dose)
OR
Levofloxacinc <50 kg: 16 mg/kg/day, PO, divided every 12 h (not to exceed 250 mg/dose) >50 kg: 500 mg, PO, given 
every 24 h
OR
2. For penicillin-susceptible strainsb,d
Amoxicillin, 75 mg/kg/day, PO, divided every 8 h (not to exceed 1 g/dose)
OR
Penicillin VK, 50–75 mg/kg/day, PO, divided every 6 to 8 h
Duration of Therapy: 60 days after exposure
Bold font: preferred antimicrobial agent (when 2 bolded antimicrobial agents are present, both are considered equivalent in 
overall safety and efficacy).
Normal font: alternative selections are listed in order of preference for therapy for patients who cannot take first-line 
therapy or if first-line therapy is unavailable.
Doses are provided for children with normal renal and hepatic function. Doses may vary for those with some degree of 
organ failure.
Italicized font: indicates FDA approval for the indication in the pediatric population.
a
A single 14-day course of doxycycline is not routinely associated with tooth staining, but some degree of staining is likely 
for a prolonged treatment course of up to 60 days.
b
On the basis of in vitro susceptibility data.
c
Safety data for levofloxacin in the pediatric population are limited to 14 days for duration therapy.
d
Be aware of the possibility of emergence of penicillin-resistance during monotherapy with amoxicillin or penicillin.
Bradley et al. Page 22













APPENDIX 2 Treatment of Cutaneous Anthrax Without Systemic 
Involvement (for Children 1 Month of Age and Older)
1. For all strains, regardless of penicillin susceptibility or if susceptibility is unknown
Ciprofloxacin, 30 mg/kg/day, by mouth (PO), divided every 12 h (not to exceed 500 mg/dose)
OR
Doxycyclinea <45 kg: 4.4 mg/kg/day, PO, divided every 12 h (not to exceed 100 mg/dose) ≥45 kg: 100 mg/dose, PO, 
given every 12 h
OR
Clindamycin,b 30 mg/kg/day, PO, divided every 8 h (not to exceed 600 mg/dose)
OR
Levofloxacin <50 kg: 16 mg/kg/day, PO, divided every 12 h (not to exceed 250 mg/dose) >50 kg: 500 mg, PO, given 
every 24 h
OR
2. Alternatives for penicillin-susceptible strainsc
Amoxicillin, 75 mg/kg/day, PO, divided every 8 h (not to exceed 1 g/dose)
OR
Penicillin VK, 50–75 mg/kg/day, PO, divided every 6 to 8 h
Duration of therapy:
For naturally acquired infection: 7–10 days.
For a biological weapon–related event: will require additional prophylaxis for inhaled spores, to complete an 
antimicrobial course of up to 60 days
from onset of illness (see Appendix 1, Postexposure Prophylaxis).
Bold font: preferred antimicrobial agent.
Normal font: alternative selections are listed in order of preference for therapy for patients who cannot take first-line 
therapy or if first-line therapy is unavailable.
Doses are provided for children with normal renal and hepatic function. Doses may vary for those with some degree of 
organ failure.
Italicized font: indicates FDA approval for the indication in the pediatric population.
a
A single 10- to 14-day course of doxycycline is not routinely associated with tooth staining.
b
On the basis of in vitro susceptibility data.
c
Be aware of the possibility of emergence of penicillin-resistance during monotherapy with amoxicillin or penicillin.
APPENDIX 3 Combination Therapy for Systemic Anthrax When Meningitis 
Can Be Ruled Out (for Children 1 Month of Age and Older)
1. A bactericidal antimicrobial
a. For all strains, regardless of penicillin susceptibility or if susceptibility is unknown
Ciprofloxacin, 30 mg/kg/day, intravenously (IV), divided every 8 h (not to exceed 400 mg/dose)
OR
Meropenem, 60 mg/kg/day, IV, divided every 8 h (not to exceed 2 g/dose)
OR
Levofloxacin <50 kg: 20 mg/kg/day, IV, divided every 12 h (not to exceed 250 mg/dose >50 kg: 500 mg, IV, given 
every 24 h
OR
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Imipenem/cilastatin,a 100 mg/kg/day, IV, divided every 6 h (not to exceed 1 g/dose)
OR
Vancomycin, 60 mg/kg/day, IV, divided every 8 h (follow serum concentrations)
b. Alternatives for penicillin-susceptible strains
Penicillin G, 400 000 U/kg/day, IV, divided every 4 h (not to exceed 4 MU/dose)
OR
Ampicillin, 200 mg/kg/day, IV, divided every 6 h (not to exceed 3 g/dose)
PLUS
2. A Protein Synthesis Inhibitor
Clindamycin, 40 mg/kg/day, IV, divided every 8 h (not to exceed 900 mg/dose)
OR
Linezolidb (non-CNS infection dose): <12 y old: 30 mg/kg/day, IV, divided every 8 h≥12 y old: 30 mg/kg/day, IV, 
divided every 12 h (not to exceed 600 mg/dose)
OR
Doxycyclinec <45 kg: 4.4 mg/kg/day, IV, loading dose (not to exceed 200 mg); ≥45 kg: 200 mg, IV, loading dose then 
<45 kg: 4.4 mg/kg/day, IV, divided every 12 h (not
to exceed 100 mg/dose); ≥45 kg: 100 mg, IV, given every 12 h
OR
Rifampin,d 20 mg/kg/day, IV, divided every 12 h (not to exceed 300 mg/dose)
Duration of therapy: For 14 days or longer until clinical criteria for stability are met (see text). Will require 
prophylaxis to complete an antimicrobial
course of up to 60 days from onset of illness (see Appendix 1).
Systemic anthrax includes inhalation anthrax; injection, gastrointestinal, or cutaneous anthrax with systemic involvement, 
extensive edema, or lesions of the head or neck.
Children with altered mental status, signs of meningeal inflammation, or focal neurologic deficits should be considered to 
have CNS infection if CSF examination is not possible. A normal CSF may not completely exclude deep brain hemorrhage/
abscess. See Appendix 4 for therapy of CNS infection.
Bold font: preferred antimicrobial agent.
Normal font: alternative selections are listed in order of preference for therapy for patients who cannot tolerate first-line 
therapy or if first-line therapy is unavailable.
Doses are provided for children with normal renal and hepatic function. Doses may vary for those with some degree of 
organ failure.
a
Increased risk of seizures associated with imipenem/cilastatin therapy.
b
Linezolid should be used with caution in patients with thrombocytopenia, as it may exacerbate it. Linezolid use for >14 
days carries additional hematopoietic toxicity.
c
A single 14-day course of doxycycline is not routinely associated with tooth staining.
d
Rifampin is not a protein synthesis inhibitor; it may also be used in combination therapy based on in vitro synergy.
APPENDIX 4 Triple Therapy for Systemic Anthrax (Anthrax Meningitis or 
Disseminated Infection and Meningitis Cannot Be Ruled Out) for Children 1 
Month of Age and Older
1. A bactericidal antimicrobial (fluoroquinolone)
Ciprofloxacin, 30 mg/kg/day, intravenously (IV), divided every 8 h (not to exceed 400 mg/dose)a
OR
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Levofloxacin <50 kg: 16 mg/kg/day, IV, divided every 12 h (not to exceed 250 mg/dose); >50 kg: 500 mg, IV, every 24 
h
OR
Moxifloxacin 3 mo to <2 y: 12 mg/kg/day, IV, divided every 12 h (not to exceed 200 mg/dose)
2–5 y: 10 mg/kg/day, IV, divided every 12 h (not to exceed 200 mg/dose)
6–11 y: 8 mg/kg/day, IV, divided every 12 h (not to exceed 200 mg/dose)
12–17 y, ≥45 kg body weight: 400 mg, IV, once daily
12–17 y, <45 kg body weight: 8 mg/kg/day, IV, divided every 12 h (not to exceed 200 mg/dose)
PLUS
2. A bactericidal antimicrobial (β-lactam or glycopeptide)
a. For all strains, regardless of penicillin susceptibility testing or if susceptibility is unknown
Meropenem, 120 mg/kg/day, IV, divided every 8 h (not to exceed 2 g/dose)
OR
Imipenem/cilastatin,b 100 mg/kg/day, IV, divided every 6 h (not to exceed 1 g/dose)
OR
Doripenem,c 120 mg/kg/day, IV, divided every 8 h (not to exceed 1 g/dose)
OR
Vancomycin, 60 mg/kg/day, IV, divided every 8 h
b. Alternatives for penicillin-susceptible strains
Penicillin G, 400 000 U/kg/day, IV, divided every 4 h (not to exceed 4 MU/dose)
OR
Ampicillin, 400 mg/kg/day, IV, divided every 6 h (not to exceed 3 g/dose)
PLUS
3. A Protein Synthesis Inhibitor
Linezolidd: <12 y old: 30 mg/kg/day, IV, divided every 8 h≥12 y old: 30 mg/kg/day, IV, divided every 12 h (not to 
exceed 600 mg/dose)
OR
Clindamycin, 40 mg/kg/day, IV, divided every 8 h (not to exceed 900 mg/dose)
OR
Rifampin,e 20 mg/kg/day, IV, divided every 12 h (not to exceed 300 mg/dose)
OR
Chloramphenicol,f 100 mg/kg/day, IV, divided every 6 h
Duration of therapy: for 2–3 wk or greater, until clinical criteria for stability are met (see text). Will require 
prophylaxis to complete an antimicrobial
course of up to 60 days from onset of illness (see Appendix 1).
Systemic anthrax includes anthrax meningitis; inhalation anthrax; or injection, gastrointestinal, and cutaneous anthrax with 
systemic involvement, extensive edema, or lesions of the head or neck.
Children with altered mental status, signs of meningeal inflammation, or focal neurologic deficits should be considered to 
have CNS infection if CSF examination is not possible. Normal CSF may not completely exclude deep brain hemorrhage/
abscess.
Bold font: preferred antimicrobial agent.
Normal font: alternative selections are listed in order of preference for therapy for patients who cannot tolerate first-line 
therapy or if first-line therapy is unavailable.
Doses are provided for children with normal renal and hepatic function. Doses may vary for those with some degree of 
organ failure.
a
A 400-mg dose of ciprofloxacin, IV, provides an equivalent exposure to that of a 500-mg ciprofloxacin oral tablet.
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Increased risk of seizures associated with imipenem/cilastatin therapy.
c
Doripenem is approved in Japan at this dose for the treatment of community-acquired bacterial meningitis.
d
Linezolid should be used with caution in patients with thrombocytopenia, as it may exacerbate it. Linezolid use for >14 
days carries additional hematopoietic toxicity.
e
Rifampin is not a protein synthesis inhibitor; it may also be used in combination therapy based on in vitro synergy for 
some strains of staphylococci. Not evaluated for B anthracis.
f
Should be used only if other options are not available, because of toxicity concerns.
APPENDIX 5 Oral Follow-up Combination Therapy for Severe Anthrax (for 
Children 1 Month of Age and Older)
1. A bactericidal antimicrobial
a. For all strains, regardless of penicillin susceptibility or if susceptibility is unknown
Ciprofloxacin, 30 mg/kg/day, by mouth (PO), divided every 12 h (not to exceed 500 mg/dose)
OR
Levofloxacin <50 kg: 16 mg/kg/day, PO, divided every 12 h (not to exceed 250 mg/dose) ≥50 kg: 500 mg, PO, given 
every 24 h
OR
b. Alternatives for penicillin-susceptible strains
Amoxicillin, 75 mg/kg/day, PO, divided every 8 h (not to exceed 1 g/dose)
OR
Penicillin VK, 50–75 mg/kg/day, PO, divided every 6 to 8 h
PLUS
2. A protein synthesis inhibitor
Clindamycina 30 mg/kg/day, PO, divided every 8 h (not to exceed 600 mg/dose)
OR
Doxycyclineb <45 kg: 4.4 mg/kg/day, PO, divided every 12 h (not exceed 100 mg/dose) ≥45 kg: 100 mg, PO, given 
every 12 h
OR
Linezolidc (non-CNS infection dose):
<12 y old: 30 mg/kg/day, PO, divided every 8 h
≥12 y old: 30 mg/kg/day, PO, divided every 12 h
(not to exceed 600 mg/dose)
Duration of therapy: to complete a treatment course of 14 days or greater. May require prophylaxis to complete 
an antimicrobial course of up to 60
days from onset of illness (see Appendix 1).
Severe anthrax includes inhalation anthrax; injection, gastrointestinal, or cutaneous anthrax with systemic involvement, 
extensive edema, or lesions of the head or neck.
Bold font: preferred antimicrobial agent.
Normal font: alternative selections are listed in order of preference for therapy for patients who cannot take first-line 
therapy or if first-line therapy is unavailable.
Doses are provided for children with normal renal and hepatic function. Doses may vary for those with some degree of 
organ failure.
a
Based on in vitro susceptibility data rather than studies of clinical efficacy.
b
A single 14-day course of doxycycline is not routinely associated with tooth staining.
c
Linezolid should be used with caution in patients with thrombocytopenia, as it may exacerbate it. Linezolid use for >14 
days carries additional hematopoietic toxicity.
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APPENDIX 6 Dosing in Preterm and Term Neonates 32 to 44 Weeks’ 
Postmenstrual Age (Gestational Age Plus Chronologic Age)
THESE ANTIMICROBIALS AND DOSAGES HAVE NOT BEEN REVIEWED OR APPROVED BY THE FDA FOR USE IN NEWBORN 
INFANTS, UNLESS SPECIFICALLY NOTED.
THESE DOSES ARE PROVIDED ONLY AS GUIDANCE DURING AN EMERGENCY BIOLOGICAL WEAPON EVENT, ON THE BASIS 
OF AVAILABLE LITERATURE OR
EXTRAPOLATION FROM PHARMACOKINETIC DATA FROM OLDER CHILDREN, WITH KNOWLEDGE OF MATURATION OF 
NEONATAL CLEARANCE MECHANISMS.
Dosing guidance for anthrax in newborn infants has not been proposed earlier because of the paucity of pharmacologic data describing kinetics, 
safety,
and efficacy and the broad range of developmental changes that will affect therapy in this immature population. This guidance accommodates not
only term newborn infants but also neonates who may be born at 32 wk postmenstrual age (PMA). For neonates of earlier gestational age, please
consult with a neonatologist, pharmacologist, or infectious diseases physician for appropriate dosing. Doses are provided for newborns with
developmentally appropriate renal and hepatic function. Doses may vary for those with some degree of organ failure.
By convention, the neonatal period ends 28 d (4 wk) after birth, but at 4 wk of age, the physiologic maturity of a preterm infant lags significantly 
behind
a term infant. Preterm infants continue to undergo developmental changes through 44 wk PMA that affect pharmacokinetics, with maturation of
mechanisms of renal elimination and hepatic enzymatic drug inactivation that occur at different rates for different antimicrobial agents, some 
closely
linked to PMA or chronologic age, but most demonstrate aspects of both. Hence, we provide guidance for all newborn infants through 44 wk 
PMA while
recognizing that many physiologic processes mature during this developmental period and that new dosing recommendations are likely to follow
as additional data become available. Should these medications be required for treatment or prophylaxis, it will be especially important to plan
prospectively to monitor serum/plasma concentrations in a systematic fashion to acquire good data that relate dose of drug to concentration,
efficacy, and occurrence of adverse effects.
Antimicrobial-related adverse effects are always possible; however, the benefit of antimicrobial therapy for life-threatening infection justifies 
assuming
greater risk during therapy. In general, the frequency and severity of adverse events seem to be less, rather than more, in neonates.
A. Triple therapy for severe anthraxa (anthrax meningitis or disseminated infection and meningitis cannot be ruled outb)
Duration of therapy: For ≥2–3 wk, until clinical criteria for stability are met (see text). Will require prophylaxis to complete an antibiotic course 
of up
to 60 days from onset of illness (see Appendix 6E).
Antimicrobial84 32–34 wk Gestational Age 34–37 wk Gestational Age Term Newborn Infant
0–1 wk of Age 1–4 wk of Age 0–1 wk of Age 1–4 wk of Age 0–1 wk of Age 1–4 wk of Age
1. A bactericidal antimicrobial (fluoroquinolone)













Levofloxacin IV88 — — — — — —
OR







2. A bactericidal antimicrobial (β-lactam)
a. For all strains, regardless of penicillin susceptibility or if susceptibility is unknown
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b. Alternatives for penicillin-susceptible strains





















































































B. Therapy for severea anthrax when meningitis can be ruled outb
Duration of therapy: For ≥2–3 wk, until clinical criteria for stability are met (see text). Will require prophylaxis to complete an antimicrobial 
course of up
to 60 days from onset of illness (see Appendix 6E).
1. A bactericidal 
antimicrobial
a. For all strains, regardless of penicillin susceptibility or if susceptibility is unknown
32–34 wk Gestational Age 34–37 wk Gestational Age Term Newborn Infant
0–1 wk of Age 1–4 wk of Age 0–1 wk of Age 1–4 wk of Age 0–1 wk of Age 1–4 wk
of Age


























Levofloxacin IV — — — — — —
OR















serum creatinine for 
infants ≥32





Serum creatinine <0.7 15 mg/kg/dose q12h
Serum creatinine 0.7 −0.9 20 mg/kg/dose q24h
Serum creatinine 1–1.2 15 mg/kg/dose q24h
Serum creatinine 1.3–1.6 10 mg/kg/dose q24h
Serum creatinine >1.6 15 mg/kg/dose q48h
Begin treatment with a 20-mg/kg loading dose
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b. Alternatives for penicillin-susceptible strains





























2. A protein 
synthesis inhibitor













































C. Oral follow-up combination therapy for severea anthrax
Duration of therapy: to complete a treatment course of 10–14 days or greater. May require prophylaxis to complete an antimicrobial course of up 
to
60 days from onset of illness (see Appendix 6E, Postexposure Prophylaxis).
1. A bactericidal antimicrobial
a. For all strains, regardless of penicillin susceptibility or if susceptibility is unknown
32–34 wk Gestational Age 34–37 wk Gestational Age Term Newborn Infant
Ciprofloxacinh PO
0–1 wk of Age
20 mg/kg/day
divided q12h
1–4 wk of Age
20 mg/kg/day
divided q12h
0–1 wk of Age
20 mg/kg/day
divided q12h
1–4 wk of Age
20 mg/kg/day
divided q12h
0–1 wk of Age
30 mg/kg/day
divided q12h




Levofloxacin PO — — — — — —
OR
b. Alternatives for penicillin-susceptible strains


























2. A protein 
synthesis inhibitor
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D. Treatment of cutaneous anthrax without systemic involvement
Duration of therapy:
For naturally acquired infection: 7–10 days
For a biological weapon–related event, may require additional prophylaxis for inhaled spores to complete an antimicrobial course of up to
60 days from onset of illness (see Appendix 6E).
1. For all strains, regardless of penicillin susceptibility or if susceptibility is unknown
32–34 wk Gestational Age 34–37 wk Gestational Age Term Newborn Infant
Ciprofloxacinh PO
0–1 wk of Age
20 mg/kg/day
divided q12h
1–4 wk of Age
20 mg/kg/day
divided q12h
0–1 wk of Age
20 mg/kg/day
divided q12h
1–4 wk of Age
20 mg/kg/day
divided q12h
1–4 wk of Age
30 mg/kg/day,
divided q12h

























Levofloxacinh PO — — — — — —
OR
2. Alternatives for penicillin-susceptible strains

























E. Postexposure prophylaxis for Bacillus anthracis
Duration of therapy: 60 days from exposure
1. For all strains, regardless of penicillin susceptibility or if susceptibility is unknown
32–34 wk Gestational Age 34–37 wk Gestational Age Term Newborn Infant
Ciprofloxacinh PO
0–1 wk of Age
20 mg/kg/day
divided q12h
1–4 wk of Age
20 mg/kg/day
divided q12h
0–1 wk of Age
20 mg/kg/day
divided q12h
1–4 wk of Age
20 mg/kg/day
divided q12h
0–1 wk of Age
30 mg/kg/day
divided q12h

























Levofloxacinh PO — — — — — —
OR
2. Alternatives for penicillin-susceptible strains
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div, XXX; q, every.
Bold font: preferred antimicrobial agent.
Normal font: alternative selections are listed in order of preference for therapy for patients who cannot tolerate first-line 
therapy, or if first-line therapy is unavailable.
a
Severe anthrax includes anthrax meningitis; inhalation anthrax; or injection, gastrointestinal, or cutaneous anthrax with 
systemic involvement; extensive edema; or lesions of the head or neck.
b
Neonates with irritability, vital sign instability, bulging fontanel, or focal neurologic deficits should be considered to have 
CNS infection if CSF examination is not possible. Normal CSF may not completely exclude deep brain hemorrhage/
abscess.
c
Increased risk of seizures associated with imipenem/cilastatin therapy.
d
Doripenem is approved in Japan at this dose for the treatment of community-acquired bacterial meningitis in older 
children.
e
Linezolid should be used with caution in newborn infants with thrombocytopenia, as it may exacerbate it. Linezolid use 
for >14 days may be associated with additional hematopoietic toxicity.
f
Rifampin is not a protein synthesis inhibitor; it also may be used in combination therapy based on in vitro synergy.
g
Should be used only if other options are not available because of toxicity concerns; obtain chloramphenicol serum 
concentrations, if possible.
h
Safety data are unavailable for fluoroquinolones for duration of therapy >30 days. Tendinopathy and arthralgia have been 
reported with fluoroquinolone antimicrobial agents in ambulating animals and humans. These problems appear to be much 
less, if they occur at all, in pediatric patients, especially in newborn infants.54,112,113
i
On the basis of in vitro susceptibility data rather than studies of clinical efficacy.
j
A single 10- to 14-day course of doxycycline is not routinely associated with tooth staining in older children but may stain 
developing teeth in neonates.40,41,114
k
Be aware of the possibility of emergence of penicillin-resistance during monotherapy with amoxicillin or penicillin.
APPENDIX 7 Diagnostic Assessment and Monitoring for Systemic Anthrax 
(Based on Recommendations for Adults)
Test Unique Findings in Systemic Anthrax Infections
Initial Serial Monitoring
Complete blood cell count Marked hemoconcentration; 
thrombocytopenia may
not be present; white blood cell 
count frequently
normal
Anemia can suddenly 
develop; thrombocytopenia
onset often associated with 
hemolytic anemia;
leukocytosis usually not seen 
until severe sepsis
stage
Electrolytes, blood urea nitrogen, lactate Decreased sodium; bicarbonate can be normal even with severe 
sepsis; increased blood urea nitrogen
Liver panel, serum albumin Mild transaminitis; hypoalbuminemia related to acute infection
Prothrombin time (PT), partial thromboplastin time
(PTT), D-dimer, Fibrinogen
Normal PT/PTT at admission 
does not exclude
coagulopathy or disseminated 
intravascular
coagulopathy




dehydrogenase, fibrin split 
products. If evidence of
hemolytic anemia, assess 
ADAMTS 13 (von
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Erythrocyte sedimentation rate, C-reactive protein Useful for characterizing 
inflammatory response
Gram stain, cultures, serum for toxin assays Any accessible fluid: blood, 
sputum, cerebrospinal,
urine, wound, gastric ulcers
Cultures usually negative 
after antimicrobial agents,
but toxin may be detectable at 
multiple time points.
Cardiac enzymes (troponin) +/−B-type natriuretic
peptide
Troponin leak as a result of increased cardiac demands from 
acute infection (especially if atrial fibrillation
with rapid ventricular response)
Electrocardiogram/continuous cardiorespiratory
monitoring telemetry
Atrial fibrillation with rapid ventricular response commonly 
observed.
Posterior-anterior and lateral chest radiograph Any abnormality: mediastinal 
widening may not be
seen in inhalation and pleural 
effusion can be
subtle
Daily chest radiographs or 
other thoracic imaging
until pleural effusions are 
stable or decreasing
Chest CT Evaluate for severity of pleural 
effusions, presence of
mediastinal widening, and to 
rule out
thromboembolic disease with 
CT angiography
Repeat if significant clinical 
status change.
Ultrasonography of the chest 
may be useful for
following pleural effusion.
Lumbar puncture With severe or systemic 
disease, perform as soon as
clinically feasible; meningeal 
signs are usually not
present until late stage, if 
meningitis is present.
—




Echocardiogram Evaluate for pericardial effusion in addition to myocardial 
dysfunction.
APPENDIX 8 Recommendations for Compatibility of Antimicrobial Agents 
and Breastfeeding
Antimicrobial Agent US National Library of Medicine LACTMEDa Briggs’ Pregnancy and Lactationb
Amoxicillin Acceptable to use Compatible
Ampicillin Acceptable to use Compatible
Chloramphenicol Alternate drug is preferred Potential toxicity
Ciprofloxacin Short-termc use is acceptable Limited human data—potential toxicity
Clindamycin Not a reason to discontinue breastfeeding
Alternate drug is preferred
Compatible
Doxycycline Short-term use is acceptable Avoid prolongedd
or repeat courses
Compatible
Imipenem Acceptable to use Limited human data—probably 
compatible
Levofloxacin Short-termc use is acceptable Limited human data—probably 
compatible
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Antimicrobial Agent US National Library of Medicine LACTMEDa Briggs’ Pregnancy and Lactationb
Linezolid Not a reason to discontinue breastfeeding No human data—potential toxicity
Meropenem Not expected to cause adverse effect No human data—probably compatible
Moxifloxacin Short-termc use is acceptable No human data—probably compatible
Penicillin Acceptable to use Compatible




Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal 




More than 14 days.
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